4篇
您的检索式：作者名="Edouard Nice"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Redox regulation in tumor cell epithelial-mesenchymal transition:molecular basis and therapeutic strategy显示文摘Epithelial–mesenchymal transition(EMT)is recognized as a driving force of cancer cell metastasis and drug resistance,two leading causes of cancer recurrence and cancer-related death.It is,therefore,logical in cancer therapy to target the EMT switch to prevent such cancer metastasis and recurrence.Previous reports have indicated that growth factors(such as epidermal growth factor and fibroblast growth factor)and cytokines(such as the transforming growth factor beta(TGF-β)family)are major stimulators of EMT.However,the mechanisms underlying EMT initiation and progression remain unclear.Recently,emerging evidence has suggested that reactive oxygen species(ROS),important cellular secondary messengers involved in diverse biological events in cancer cells,play essential roles in the EMT process in cancer cells by regulating extracellular matrix(ECM)remodeling,cytoskeleton remodeling,cell–cell junctions,and cell mobility.Thus,targeting EMT by manipulating the intracellular redox status may hold promise for cancer therapy.Herein,we will address recent advances in redox biology involved in the EMT process in cancer cells,which will contribute to the development of novel therapeutic strategies by targeting redox-regulated EMT for cancer treatment. | Jingwen Jiang Kui Wang Yan Chen Haining Chen Edouard C Nice Canhua Huang | 2017 | Signal Transduction and Targeted Therapy2017，2，1： | 5 |
| 2 | Colorectal cancer biomarkers: To be or not to be? Cautionary tales from a road well travelled显示文摘Colorectal cancer(CRC)is the second most common cause of cancer-related death worldwide and places a major economic burden on the global health care system.The time frame for development from premalignant to malignant disease typically spans 10-15 years,and this latent period provides an ideal opportunity for early detection and intervention to improve patient outcomes.Currently,early diagnosis of CRC is hampered by a lack of suitable non-invasive biomarkers that are clinically or economically acceptable for populationbased screening.New blood-based protein biomarkers for early detection of CRC are therefore urgently required.The success of clinical biomarker discovery and validation studies is critically dependent on understanding and adjusting for potential experimental,analytical,and biological factors that can interfere with the robust interpretation of results.In this review we outline some important considerations for research groups undertaking biomarker research with exemplars from our studies.Implementation of experimental strategies to minimise the potential effects of these problems will facilitate the identification of panels of biomarkers with the sensitivity and specificity required for the development of successful tests for the early detection and surveillance of CRC. | Kim YC Fung Edouard Nice Ilka Priebe Damien Belobrajdic Aloke Phatak Leanne Purins Bruce Tabor Celine Pompeia Trevor Lockett Timothy E Adams Antony Burgess Leah Cosgrove | 2014 | World Journal of Gastroenterology2014，20，4： | 2 |
| 3 | The Crystal Structure of a Truncated ErbB2 Ectodomain Reveals an Active Conformation, Poised to Interact with Other ErbB Receptors显示文摘 | Thomas P.J. Garrett Neil M. McKern Meizhen Lou Thomas C. Elleman Timothy E. Adams George O. Lovrecz Michael Kofler Robert N. Jorissen Edouard C. Nice Antony W. Burgess Colin W. Ward | 2003 | Molecular Cell2003，，2： | 1 |
| 4 | Murine fecal proteomics: A model system for the detection of potential biomarkers for colorectal cancer显示文摘 | Ching-Seng Ang Julie Rothacker Heather Patsiouras Antony W. Burgess Edouard C. Nice | 2009 | Journal of Chromatography A2009，，19： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员